Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option PlayInvestors Business Daily • 10/19/22
90-Day Analysis Shows Moderna's Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype BoosterAccesswire • 10/19/22
Moderna, Gavi cancel COVID-19 vaccine orders for rest of 2022 due to 'sufficient supply'Market Watch • 10/17/22
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income CountriesAccesswire • 10/17/22
Merck And Moderna Move Forward With Melanoma Vaccine - There's A Case For Backing BothSeeking Alpha • 10/13/22
Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022Accesswire • 10/13/22
Moderna and Merck ink US$250mln deal to develop world's first cancer vaccineProactive Investors • 10/13/22
Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccineBusiness Insider • 10/12/22